Cytiva’s direct RT-qPCR chemistry broadens the spectrum of viral nucleic acids targets and pathogens that can be detected directly from unpurified samples, reducing the time required for nucleic acid amplification testing (NAAT) and increasing RNA stability in the sample.

Sera-Xtracta Virus Pathogen Kit gives efficient total nucleic acid (DNA/RNA) recovery from swabs, biofluids and transport media and in different concentrations with high sensitivity in downstream detection. The data suggests that this kit and the RNAspin Mini Kit can help address the demand for a universal extraction kit which copurifies both DNA and RNA or just RNA and can help address the current challenges faced with supplying kits for COVID-19 testing.

Our online application notes library allows you to search for independent, peer-reviewed scientific articles and case studies which demonstrate the performance and clinical success of products from across our portfolio when used with different technologies such as NGS or microarrays, or different sample types such as FFPE or blood.

Genome sequencing allows disease diagnosis at an earlier stage and with the discovery of relevant biomarkers it means that more targeted therapeutic interventions can be provided. The trend towards a more personalized approach to healthcare is one reason for the continued growth in molecular diagnostics.

Our custom biology, conjugation, contract manufacturing and Lyo-Stable solutions can be tailored to your needs, enabling faster commercialization of your assay with minimal disruption to your existing protocols.